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Monocytes in SLE have been described as having aberrant behavior in a number of assays. We examined gene expression and
used a genome-wide approach to study the posttranslational histone mark, H4 acetylation, to examine epigenetic changes in SLE
monocytes. We compared SLE monocyte gene expression and H4 acetylation with three types of cytokine-treated monocytes to
understand which cytokine eﬀects predominated in SLE monocytes. We found that γ-interferon and α-interferon both replicated
a broad range of the gene expression changes seen in SLE monocytes. H4 acetylation in SLE monocytes was overall higher than
in controls and there was less correlation of H4ac with cytokine-treated cells than when gene expression was compared. A set of
chemokine genes had downregulated expression and H4ac. Therefore, there are signiﬁcant clusters of aberrantly expressed genes
in SLE which are strongly associated with altered H4ac, suggesting that these cells have experienced durable changes to their
epigenome.
1.Introduction
Systemic lupus erythematosus (SLE) has long been charac-
terized as a disease associated with the overexpression of
proinﬂammatory cytokines. The early studies focused on
proinﬂammatory genes and identiﬁed increased serum levels
of TNFα,I L - 6 ,γIFN, and IL-10 [1–6]. When cells have
been examined directly, either by ﬂow cytometry or culture
techniques, γIFN, IL-10, IL-17, and IL-6 have been found to
be increased in SLE patients [7–12]. In contrast, studies have
generally supported an underexpression of IL-12, which is
classically considered a proinﬂammatory cytokine [13, 14].
More recently, studies have identiﬁed a signature of type
I interferons in whole blood using gene expression arrays
[15–19]. This has generated a sea change in the etiologic
modeling of the disease and has led to a clinical trial using
a neutralizing antibody [20].
Other studies have sought to identify altered expression
of chemokines in SLE and these studies have demonstrated
increased RANTES, and MCP-1 [21, 22]. Indeed, urine
chemokine detection shows promise as an early biomarker
of nephritis [23, 24]. Chemokines are often secondary
regulatorsofcellmigration,inducedbycuesfromothercells.
This study deﬁned gene expression alterations in mono-
cytes from patients with SLE and correlated those changes
with cytokine-induced gene expression changes. We further
evaluated H4 acetylation (H4ac) changes, as H4ac is an epi-
geneticmarkoftranscriptionalpotential[25,26].Monocytes
were selected for study because monocytes and their tissue
counterpart, the macrophage, play an extremely important
role in systemic lupus erythematosus (SLE). Macrophage
inﬁltration into end organs is thought to be critical to
the disease process and renal inﬁltration of macrophages is
speciﬁcally associated with a poor prognosis [27]. Monocyte
inﬁltration into glomeruli is driven by fractalkine and
both fractalkine levels and monocyte numbers in glomeruli
correlatewithBUN,proteinuria,andGFR[28].Additionally,
increased macrophage migration inhibitory factor levels
correlate with disease activity in lupus patients [29]. Addi-
tional well-characterized roles for monocytes in SLE include
the clearance of apoptotic cells, participation in atheroma
formation, and the elaboration of inﬂammatory cytokines
[30–37].
Monocytes have long been recognized as exhibiting aber-
rant behavior in patients with systemic lupus erythematosus2 Journal of Biomedicine and Biotechnology
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Figure 1:CellsurfacemarkersarealteredinSLEandcytokine-treated
monocytes. Control monocytes were either mock treated or treated
with the indicated cytokines for 18 hours (n = 3). The SLE cells
were studied without any intervention (n = 4). In each case, the
cells were gated on physical parameters and CD14 expression. The
SLE monocytes have statistically signiﬁcant diﬀerent expression of
CD16 compared to the αIFN-treated cells.
(SLE) [38–42]. The behavior has been variously ascribed
to the presence of cytokines, the presence of immune
complexes, or inherited polymorphisms, which collectively
alter the cells’ behavior. The literature on monocytes in
SLE is consistent in demonstrating that the monocytes have
compromised viability [36, 43] have an altered capacity to
develop into dendritic cells (DC) [37, 44, 45]a n dh a v e
compromised uptake of apoptotic debris [46–49]. STAT 1
is phosphorylated in monocytes of patients with SLE and
cells have upregulated MHC class I [15, 50], consistent with
a monocyte response to type I interferons in SLE [16, 17, 19,
51–53].
Patients with SLE have mildly altered monocytes as
deﬁned by cell surface markers [54, 55], however, cytokine
expression is clearly aberrant [56, 57]. SLE monocytes are
generally reported to overproduce IL-1RA [58], IL-6 [59,
60], and TNFα in vitro [55, 61], while IL-12 production
in both humans and mice is diminished [62–64]. To better
deﬁne disease eﬀects on SLE monocytes, we examined gene
expressionchangesinpuriﬁedSLEmonocytesandcompared
those to gene expression changes in control monocytes
treated with diﬀerent cytokines. To determine whether any
of the gene expression changes could be mediated by altered
chromatin, we examined H4ac, as a mark of transcriptional
competence [65–67].
2. Methods
2.1. Cells and Reagents. The SLE monocyte gene expression
and ChIP-chip data have been previously reported [68]. In
both cases, healthy control donors were used to establish
the baseline. The samples studied here are ﬁve controls
and 9 patients. The patients had a very low SLEDAI score
(mean score 0.6) and were on no immune suppressive
medications at the time other than low dose prednisone. The
cytokine-treated monocytes utilized the cells from a single
donor for each set of cytokine treatments. The cytokine
data were reported initially in a separate study (submitted).
The data represent the averages of three diﬀerent donors.
The cells were puriﬁed by elutriation and were ≥95% pure
by CD14 staining. The cells were treated with 50ng/ml of
IL-4, 50ng/ml of γIFN (R&D Systems, Minneapolis, MN),
or 500IU/ml of αIFN (PBL Interferon Source, Piscataway,
NJ) for 18 hours. Flow cytometry for cell surface markers
utilized antibodies from BD Pharmingen and were run on
a FacsCalibur instrument using appropriate isotype controls.
2.2. Microarray Experiments. The H4ac immunoprecipita-
tion wasperformedaspreviously described [69,70].Puriﬁed
DNA from the immunoprecipitation was ampliﬁed, cleaved,
and labeled using the GeneChip WT double-stranded DNA
terminal labeling kit (Aﬀymetrix, Santa Clara, CA). DNA
preparation and hybridization were all performed according
totherecommendationsfortheGeneChipHumanPromoter
1.0R array (Aﬀymetrix). The U133A 2.0 platform was used
for the expression analyses. cRNA was prepared according
to the recommendations of the manufacturer (Aﬀymetrix).
The expression experiments included nine SLE patients,
ﬁve healthy controls, and three samples of each cytokine
treatment group. The H4ac experiments included four non-
speciﬁc GST controls, six patients, ﬁve healthy controls, and
three samples of each treatment group. The data processing
hasbeenpreviouslydescribedforthecoanalysisofexpression
and H4 acetylation data [68]. Additional information about
the data processing and statistical methods is available in the
Supplemental Methods.
3. Results
3.1. SLE Monocytes Exhibit Cell Surface Marker Expression
Which Cannot Be Attributed to Single Cytokine Eﬀect. To
understand the biology of monocytes from SLE patients, we
examinedcellsurfacemarkersbyﬂowcytometry.Weselected
a variety of cell surface markers which have been implicated
in monocyte function. The cells were gated on physical
parameters and CD14. CD16, CD23, CD32, CD64, CD80,
CD197, CD206, and CCR2 expression levels were compared
between SLE monocytes and control monocytes treated for
18 hours with cytokines. Cell surface markers signiﬁcantly
altered in SLE are shown in Figure 1. γIFN treatment
was associated with increased expression of FcγRI (CD64)
and CCR7 (CD197). IL-4 treatment was associated with
increased expression of FcεRII (CD23) and the macrophage
mannose receptor (CD206). The monocytes polarized with
αIFN displayed a unique phenotype with increased CD64.
CD80 expression was not signiﬁcantly altered by any treat-
ment. The SLE monocytes expressed cell surface markers
are somewhat consistent with the monocytes treated forJournal of Biomedicine and Biotechnology 3
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Figure 2: Cluster analysis of genes upregulated by interferons. (a) A subset of genes identiﬁed by unbiased clustering analysis were responsive
to both γIFN and αIFN, but not IL-4. On average, the expression of these genes was upregulated by 36.3% in SLE. (b) Ten focus genes
identiﬁed as being upregulated in four cell types in SLE were examined in the cytokine-treated cells. These genes also exhibited increased
expression after γIFN and αIFN treatment but not IL-4 treatment.
18 hours with αIFN, but with a clear diﬀerence in CD16
expression. Although in vitro treatment with cytokines does
not perfectly replicate chronic in vivo exposure, these data
suggested that the phenotype could not be attributed to a
single cytokine exposure. We wished to examine whether
cytokinescouldbemoldingthephenotypeofSLEmonocytes
more globally. With multiple reports of elevated cytokines in
additiontotypeIinterferons,wehypothesizedthatwewould
ﬁnd footprints of other cytokine eﬀects within the monocyte
population.
3.2. Overlap between Cytokine-Induced Gene Expression and
the SLE Gene Expression. We performed pairwise com-
parisons of gene expression between SLE monocytes or
cytokine-treatedmonocytesandhealthyoruntreatedcontrol
samples. We ﬁltered the genes with P values (t test) <.05
and selected the top 200 genes with the highest or lowest
log2 ratio of group means for further study. According
to a permutation procedure, the false discovery rates of
genes up- and down-regulated in SLE were 3.1% and 6.9%,
respectively. To gain insights into the biological alterations
as a result of these gene expression changes, we further
performed Gene Ontology (GO) analysis through DAVID
functional annotation [71]. Table 1 summarizes the top
ﬁve nonredundant GO terms enriched in SLE or cytokine
upregulated genes. The αIFN and γIFN GO terms were
similar and partly overlaped the SLE terms, indicating that
theSLEmonocytesunderwentsomegeneexpressionchanges
similar to the eﬀect of interferon treatment. On the other
hand, IL-4 terms had little similarity to SLE and interferon
terms. This as expected because Il-4 has not been implicated
in SLE and was included as a control.
As interferons and IL-4 caused distinctive gene expres-
sion changes in monocytes, we carried out a gene clustering
analysis on the cytokine data to identify a cluster of 187
genes that responded to both interferons, but not IL-4
(Figure 2(a)). In this cluster, DAVID analysis conﬁrmed the
enrichment of genes involved in immune system processes
in this cluster (P = 1.4e − 20) and identiﬁed seven genes
with a known relationship to SLE: FAS, CFB, CCR5, CD80,
TRIM21, TAP1, and TAP2. The whole cluster was generally
upregulatedinSLE(P = 3.4e−14) withanaverageincrease
of 36.3%. Further investigation of this gene cluster could
reveal more details about the unique roles of interferons in
SLE.
We also compared our SLE data with those of an
independent study, in which puriﬁed CD4 T cells, CD19 B
cells, and myeloid cells from patients with SLE were used
as sources for gene expression arrays [72]. The raw data
from the study were downloaded from the GEO database
(GSE10325) and processed with the same procedure used
in this study. The top 200 upregulated genes were identiﬁed
with the same criteria from each cell type and ten of them
were included in the lists of all cell types examined, including
ourSLEmonocytes.Thesetengeneswerealsohighlyinduced
by αIFN with a smaller eﬀect seen in the γIFN-treated
cells, but slightly down-regulated by IL-4 (Figure 2(b)). This
analysis ensured that although our sample population had
very low disease activity, the ﬁndings were generalizeable.
3.3. H4 Acetylation in SLE. We have previously reported that
H4ac was altered in SLE monocytes [68, 73]. We therefore
reanalyzed the data to understand the role of the diﬀerent
cytokines in the altered H4ac landscape of the cells. The4 Journal of Biomedicine and Biotechnology
2.5 0 −2.5 −5 −7.5
Distance to TSS (k)
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
A
v
e
r
a
g
e
o
f
H
4
a
c
s
i
g
n
a
l
i
n
c
o
n
t
r
o
l
s
a
m
p
l
e
s
(a)
2.5 0 −2.5 −5 −7.5
Distance to TSS (k)
−0.2
0
0.2
0.4
0.6
C
h
a
n
g
e
o
f
H
4
a
c
s
i
g
n
a
l
i
n
S
L
E
(b)
2.5 0 −2.5 −5 −7.5
Distance to TSS (k)
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
A
v
e
r
a
g
e
o
f
H
4
a
c
s
i
g
n
a
l
i
n
c
o
n
t
r
o
l
s
a
m
p
l
e
s
(c)
2.5 0 −2.5 −5 −7.5
Distance to TSS (k)
−0.2
0
0.2
0.4
0.6
C
h
a
n
g
e
o
f
H
4
a
c
s
i
g
n
a
l
i
n
S
L
E
(d)
Figure 3: The distribution of H4ac at the promoter. (a) H4ac was distributed around the transcription start site. (b) The SLE monocytes had
increased H4ac globally around the transcription start site. (c) The average of H4ac at potential TFBSs (grey area) was diﬀerent from the
general pattern of H4ac around TSS (black line), most notably, it was higher in the promoter region, but lower immediately after the TSSs.
(d). In SLE, the average change of H4ac at potential TFBS (grey area) was also diﬀerent from the general pattern (black line).
H4ac mark was mapped using tiling arrays and all genes
were aligned by their transcription start site (TSS). The
H4ac content exhibits a forked peak pattern, centered on
the TSS (Figure 3(a))[ 66, 74]. When the SLE H4ac signal
across the genome was compared to controls, SLE genes
overall has a higher signal. Much of the diﬀerence between
the patients and controls lies around the transcription start
site, with relative hypoacetylation distant from the TSS
(Figure 3(b)). H4 acetylation marks are typically placed by
histone acetyltransferases recruited by transcription factors.
We previously reported an increase of H4ac at potential
binding sites of transcription factors like IRF1 and the
expression change of IRF1-downstream targets [68]. We
generalized our analysis in this study. All potential TFBSs in
human genome conserved in human/mouse/rat alignment
weredownloadedfromUCSCGenomeBrowserandmapped
to the TSSs. The average H4ac at binding sites around
TSSs had a distinctive pattern (Figure 3(c)). TFBSs located
in the upstream promoter region had higher H4ac than
average while those located immediately downstream of
TSS had lower H4ac content. In SLE monocytes, the H4ac
change at TFBSs had a similar pattern (Figure 3(d)). These
observations suggest that H4ac at TFBSs is part of an
expression regulatory network.
Weconsideredwhetherincreasedcompetenceforexpres-
sion of the histone genes themselves could contribute to this
picture. It may be seen that the H4ac at the H2, H3, and
H4 gene clusters was generally increased in SLE monocytes
(Figure 4). This could contribute to globally increased H4ac
in the SLE monocytes but cannot be the complete explana-
tion because the acetyl mark is placed posttranscriptionally.
Tounderstandwhetherhistoneacetyltransferasesmighthave
dysregulated expression as a mechanism to explain the
globally increased H4ac, we examined the expression of
the human histone acetyltransferases in SLE patients. The
expressionofthesegeneswasnotgloballyincreasedalthough
several individual members were upregulated including
HAT1 (log2 ratio=0.79), KAT2B (log2 ratio=0.77), MYST3
(log2 ratio=0.74), and MYST4 (log2 ratio=0.53). We
examined whether this eﬀect was replicated in any of theJournal of Biomedicine and Biotechnology 5
Table 1: DAVID analysis of SLE gene expression.
Gene List GO Term Count P value Fold Enriched
SLE UP
Immune system process 45 6.46E-15 3.78
Leukocyte activation 14 9.91E-06 4.60
Cytokine receptor activity 5 1.11E-03 10.67
Intracellular signaling cascade 32 3.73E-03 1.68
Defense response 15 2.16E-02 1.94
AIFN UP
Immune system process 57 2.34E-23 4.59
Response to virus 24 4.02E-22 16.68
Defense response 33 1.14E-11 4.09
Induction of apoptosis 10 5.04E-03 3.08
Interferon type I production 3 7.90E-03 21.38
GIFN UP
Immune system process 63 2.08E-28 5.04
Response to virus 17 5.98E-13 11.75
Defense response 34 2.62E-12 4.19
Regulation of apoptosis 20 4.35E-04 2.46
Lymphocyte proliferation 7 6.09E-04 6.61
IL4 UP
Response to external stimulus 25 2.83E-05 2.59
Ribosome biogenesis and assembly 8 3.25E-04 6.05
Cell communication 72 3.46E-04 1.43
Chemokine activity 6 5.24E-04 8.85
Lymphocyte proliferation 6 4.13E-03 5.60
Table 2: DAVID analysis of H4ac gene sets.
Gene List GO Term Count P value Fold Enriched
SLE UP
Membrane-bound organelle 114 2.39E-06 1.35
Nucleic acid binding 62 2.07E-05 1.65
Metabolic process 122 7.37E-04 1.19
Chromatin assembly 6 4.56E-03 5.44
Ribosome biogenesis and assembly 6 9.61E-03 4.57
AIFN UP
Response to virus 13 1.10E-08 9.16
Immune system process 35 3.27E-08 2.84
Structural constituent of ribosome 7 6.30E-03 4.18
Defense response 17 9.08E-03 2.03
Interferon type I production 3 1.20E-02 17.17
GIFN UP
Immune system process 40 9.04E-11 3.17
Late endosome 7 6.58E-05 9.70
Defense response 22 1.13E-04 2.56
Response to virus 8 5.58E-04 5.50
Adaptive immune response 6 5.73E-03 5.16
IL4 UP
Antigen processing and presentation 7 2.08E-04 7.96
Immune system process 23 4.08E-03 1.90
Regulation of protein metabolic process 11 8.14E-03 2.66
Structural molecule activity 17 2.69E-02 1.79
Golgi vesicle transport 6 2.90E-02 3.45
cytokine-treated monocytes. Only KAT2B was upregulated
in γIFN and αIFN-treated cells, which is consistent with the
observation that H4ac is globally elevated in SLE monocytes
but not in cytokine-treated cells.
To examine the biological processes anticipated to be
altered as a result of the SLE H4ac landscape, we utilized
DAVID for the GO analysis of the 200 genes with the highest
H4ac due to cytokine treatment or SLE (Table 2). This
strategy collapses the H4ac data into functional categories.
In this analysis, the ﬁnding of increased H4ac in SLE was
seen in processes related to basic cell biology, including
basic metabolic processes. Besides the GO terms listed in6 Journal of Biomedicine and Biotechnology
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Figure 4: H4ac at histone genes. H 2 ,H 3 ,a n dH 4g e n ef a m i l i e sh a d
increased H4ac in SLE monocytes.
Table 2, DAVID also found increased H4ac of the Kruppel-
associated box (KRAB) family of transcriptional repressors
in SLE monocytes (P = 8.1e − 9). These typically function
in hematopoietic cell diﬀerentiation [75]. When DAVID was
used to examine the inferred biological processes altered in
SLE compared to those in γIFN and αIFN-treated cells, there
was little overlap, suggesting that the SLE monocytes are
more fundamentally altered than can be explained by brief
cytokine exposure.
3.4. Coanalysis of H4ac and Gene Expression. To understand
whether cytokines could alter the chromatin landscape of
monocytes and to correlate the H4ac changes seen in SLE
monocytes with those induced by cytokines, we examined
the agreement between H4ac and expression data of 9553
unique genes measured by both array platforms and the
results are summarized in Table 3. The ﬁrst part of Table 3
(with GST controls) compares the absolute measurements
of expression and H4ac in six sample groups, after the GST
control was used to remove nonspeciﬁc array signals from
the H4ac data. The global correlation between expression
and H4ac was consistently around 0.4 in all groups. We
picked the 200 top and bottom genes from each group
based on their expression and H4ac level and checked the
overlap between the two lists. The numbers of overlapped
genes and the odds ratios calculated by Fisher’s test are
also listed in Table 3. The genes with high expression had
relatively less overlap with genes with high H4ac, compared
to the down-regulated pair, suggesting that high H4ac is not
suﬃcient to ensure high gene expression. The overlapping
at the lower end was much more prominent. The second
part of Table 3 (the last four lines) presents the same
results based on the relative change of expression and H4ac
within each experimental group. The relative change in
expression was calculated from the reference for each group,
given in the second column. The global expression-H4ac
correlationwasnotablylowerasmostgeneswerenotaﬀected
by SLE or cytokine treatment. The overlap between genes
with increased expression and H4ac was more signiﬁcant,
especially genes responding to interferons.
We identiﬁed two clusters of genes with an unusually
high correlation of H4ac and gene expression. A cluster of
chemokine genes that map to chromosome 4 had markedly
repressed expression in SLE and this was associated with a
markedly diminished H4ac. Interestingly, these genes were
repressed by all three cytokines. These chemokines regulate
neutrophil function, monocyte migration, and angiogenesis
[76–80]. The interferon-responsive genes had a strong
association of H4ac and gene expression in SLE and this was
replicated in part by exposure to both types of interferon
(Figure 5).
To more directly link gene expression change to histone
modiﬁcation,wesummarizedtheaverageH4acchangeofthe
genes identiﬁed above as diﬀerentially expressed in SLE or
after cytokine treatment (Figure 6). On average, genes with
upregulated expression in SLE had a dramatic increase in
H4ac. However, as the H4ac was generally increased in SLE,
the H4ac around the TSS of down-regulated genes was also
increased slightly although H4ac was notably decreased in
upstream promoter region. Genes up- or down-regulated by
cytokines had a more consistent H4ac change. An interesting
o b s e r v a t i o ni nF i g u r e6 is that the genes upregulated in SLE
seemed to have lower baseline H4ac by average, suggesting
that those genes may be repressed in healthy monocytes.
4. Discussion
The concept of an altered epigenome in SLE is an attractive
modelbecausetheepigenomecouldcontributetothedisease
perpetuation by molding pathologic gene expression. One
of the best-characterized epigenetic changes in SLE is the
hypomethylation of DNA in T cells [81]. This ﬁnding is
consistent in murine models [82] and more recent studies
have linked demethylation of DNA with the drug-induced
lupus seen with procainamide and hydralazine [83, 84].
Induced demethylation alters the expression of a number
of genes, which could contribute to the pathophysiology of
lupus [85–87].
S e v e r a lg r o u p sh a v eu t i l i z e dh i s t o n ed e a c e t y l a s e( H D A C )
inhibitors in lupus models in an eﬀort to reregulate aberrant
geneexpression. Trichostatin (TSA)orthechemicallyrelated
compound, SAHA, was used to treat MRL/lpr mice [88].
These agents increase H4ac through inhibition of histone
deacetylases. This murine model of SLE is characterized by
increased expression of γIFN, IL-12, IL-6, and IL-10. In vitro
and in vivo treatment with an HDAC inhibitor decreased
RNA and protein levels for all four overexpressed cytokines.
In addition, administration of TSA led to less active renal
disease [88]. HDAC inhibitors are immunosuppressive in
vivo and therefore to better understand the epigenome in
SLE, we directly characterized the epigenome in SLE [89].
Our previous study of H4ac in SLE monocytes found that
many of the changes could be due to overexpression of
the transcription factor IRF1 [68]. In the current study,Journal of Biomedicine and Biotechnology 7
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Figure 5: SLE is known to be associated with increased expression of interferon-inducible genes and these genes have a strong association of H4ac
and gene expression. We noted another cluster had a similarly strong association of H4ac and gene expression. The chemokine cluster was
identiﬁed as having signiﬁcantly decreased expression and H4ac in SLE monocytes. (a) The heatmap demonstrating the association of gene
expression and H4ac. (b) The statistical relationship between the groups.
we directly examined whether gene expression and H4ac
alterations in SLE monocytes could be attributed to cytokine
exposure. The SLE literature is replete with studies demon-
strating overexpression of a broad range of cytokines, not
just type I interferons. The ﬁnding of speciﬁc features
attributable to cytokine exposure would have a signiﬁcant
impact on the conceptualization of new treatments. A caveat
ofthesystemweusedisthatthecytokine-treatedcellsusedas
comparatorsrepresentanartiﬁcialinvitrosystemthatclearly
cannot replicate the complex chronic exposures seen in a
disease state. Nevertheless, this study demonstrates that such
attribution is possible and can be used to examine both the
epigenetic changes in SLE as well as gene expression.
An underlying hypothesis is that monocytes “polarized”
by the disease can contribute to ongoing inﬂammation or
may mold the end organ involvement. Supporting this is
the ﬁnding that in murine models of SLE as well as human
disease, macrophage inﬁltration into the kidney correlates
with the severity of the renal disease and the prognosis [27].
Aberrant regulation of chemokines, as demonstrated in this
study, would be predicted to alter migration and potentially
alter disease manifestations. If some of these alterations can8 Journal of Biomedicine and Biotechnology
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Figure 6: The change in gene expression in SLE or cytokine-treated samples was matched by H4ac changes in the same samples. (a) Upregulated
genes seen in SLE or after cytokine treatment were examined for H4ac content. The top 200 genes with the highest expression change caused
by SLE or cytokines, as was identiﬁed by previous analysis were included. (b) Down-regulated genes seen in SLE or after cytokine treatment
were examined for H4ac content. The 200 genes most down-regulated were examined. The black contour indicates the average H4ac in
control samples and the colored regions correspond to the amount of H4ac increase (red) or decrease (green) in SLE or cytokine-treated
samples.
Table 3: Concordance between gene expression and H4ac content.
Group 1 Group 0 Correlation (r) Top 200 overlap∗
Num gene (up) Odds Ratio (up) Num gene (down) Odds Ratio (down)
Healthy GST 0.39 8 1.99 17 4.65
SLE GST 0.44 10 2.54 24 7.11
NoRx GST 0.44 7 1.72 29 9.10
AIFN GST 0.45 10 2.54 26 7.88
GIFN GST 0.44 6 1.46 26 7.88
IL4 GST 0.43 9 2.26 31 9.96
SLE Healthy 0.21 13 3.41 22 6.37
AIFN NoRx 0.23 49 19.76 10 2.54
GIFN NoRx 0.19 34 11.32 19 5.32
IL4 NoRx 0.14 18 4.98 23 6.73
be traced to a speciﬁc signaling pathway, a novel therapeutic
target would be identiﬁed.
This study examined a speciﬁc cell type in which
dysfunction has been well characterized in humans. Murine
lupus models also exhibit aberrant monocyte function,
suggesting it is a consistent feature of the disease. Both
monocyte uptake of apoptotic cells and DNA are abnor-
mal [90–92]. Indeed, monocyte apoptosis itself may con-
tribute to the disease process [93]. Many SLE murine
models exhibit a monocytosis, and the monocytes may
amplify the inﬂammatory process [94–97]. In MRL/lpr
mice, macrophage expression of γIFN is required for the
expression of the renal disease [98]. Additional studies
demonstrated that engagement of TLR7 aggravated renal
disease, characterized by inﬁltration of monocytes [98, 99].
In fact, inhibition of macrophage recruitment into the
kidney, markedly attenuated the phenotype in MRL/lpr mice
[100]. In the NZB × NZW system, signaling in myeloid
cells through FcγR is critical to the inﬂammatory process
and macrophages are critical for anti-dsDNA productionJournal of Biomedicine and Biotechnology 9
[101, 102]. The SLE3 locus in the NZM2410 strain, derived
from NZB × NZW, appears to confer susceptibility to lupus
bydrivingincreasedmacrophagecostimulatoryactivity[103,
104]. A potential role for monocytes in these models is via
the inﬂammatory cytokines produced by monocytes and
macrophages as was demonstrated in the MRL/lpr system
[98, 99].
This study provides a potential explanation for the
persistent monocyte dysfunction seen in both human SLE
patients and in murine models. The eﬀect of cytokines can
induce changes in the epigenome and persistence of these
changes could lead to durably altered gene expression which
in turn could underlie many of the aberrant functions. There
were many other eﬀects that did not trace to the three
cytokines used in this study. Potential caveats include the
short exposure to cytokines in our model system, the eﬀects
from other cytokines or stimuli and the potential for the cells
to have an aberrant diﬀerentiation pathway in the presence
of active SLE.
This study hypothesized that many of the changes
in both gene expression and H4ac would be attributable
to type I interferons since their eﬀects have been well
characterized in SLE [16, 51, 105]. Indeed, many eﬀects
in gene expression and H4ac could be traced to αIFN,
although γIFN led to similar changes. There are several lines
of evidence suggesting that monocytes have been molded by
a complex set of exposures. Our cytokine attribution found
that the interferon-responsive genes cluster was upregulated
36.3% in SLE monocytes, thus leaving a signiﬁcant gene
set unexplained by interferon exposure. The association was
even less robust for H4ac. The ﬁnding that H4 acetylation
was globally increased and this increase appeared to map to
TFBSs suggests a globally altered epigenome with a complex
etiology. Therefore, monocytes are signiﬁcantly impacted by
both αIFN and γIFN exposure, however, our data suggest
that additional cytokines and other exposures contribute to
the aberrant monocyte behavior observed in SLE patients.
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